Search Result

Isoforms Recommended:	PDGFRα

Results for "

PDGFRα

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (8) Aurora Kinase (3) Autophagy (9) Bcr-Abl (9) c-Fms (3) c-Kit (11) c-Met/HGFR (3) c-Myc (1) Collagen (1) Discoidin Domain Receptor (1) EGFR (3) Endogenous Metabolite (1) ERK (4) FGFR (11) FLT3 (15) Haspin Kinase (1) JAK (1) MEK (2) MELK (1) Mitosis (2) Necroptosis (1) PDGFR (51) RAD51 (3) Reference Standards (6) RET (5) RIP kinase (1) Src (9) TGF-beta/Smad (1) TGF-β Receptor (1) VEGFR (23)
By Research Areas:	Cancer (47) Cardiovascular Disease (6) Endocrinology (1) Infection (3) Inflammation/Immunology (4) Neurological Disease (1)

By Targets:

Akt (2)

Apoptosis (8)

Aurora Kinase (3)

Autophagy (9)

Bcr-Abl (9)

c-Fms (3)

c-Kit (11)

c-Met/HGFR (3)

c-Myc (1)

Collagen (1)

Discoidin Domain Receptor (1)

EGFR (3)

Endogenous Metabolite (1)

ERK (4)

FGFR (11)

FLT3 (15)

Haspin Kinase (1)

JAK (1)

MEK (2)

MELK (1)

Mitosis (2)

Necroptosis (1)

PDGFR (51)

RAD51 (3)

Reference Standards (6)

RET (5)

RIP kinase (1)

Src (9)

TGF-beta/Smad (1)

TGF-β Receptor (1)

VEGFR (23)

By Research Areas:

Cancer (47)

Cardiovascular Disease (6)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (4)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12047

Ponatinib Maximum Cited Publications 50 Publications Verification AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, *PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-12050

CP-673451 20+ Cited Publications	PDGFR	Cancer
CP-673451 is a potent and selective inhibitor of *PDGFR* with IC₅₀s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.

HY-108766

Ponatinib hydrochloride Maximum Cited Publications 50 Publications Verification AP24534 hydrochloride	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy	Infection Cancer
Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, *PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-10205

Cediranib 10+ Cited Publications AZD2171	VEGFR Autophagy PDGFR	Infection Neurological Disease Inflammation/Immunology Cancer
Cediranib (AZD2171) is a highly potent, orally available and blood-brain barrier permeability VEGFR tyrosine kinase inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-10987A

ENMD-2076 4 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR PDGFR Src Apoptosis	Cancer
ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, *PDGFRα*, respectively.

HY-P9922

Olaratumab IMC-3G3; LY3012207	PDGFR	Cancer
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .

HY-124526

Chiauranib Ibcasertib; CS2164	PDGFR c-Fms Aurora Kinase VEGFR c-Kit Mitosis	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, *PDGFRα* and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-109190

Seralutinib 2 Publications Verification GB002; PK10571	PDGFR c-Fms c-Kit	Cardiovascular Disease
Seralutinib (GB002) is an inhaled *PDGFRα* and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC₅₀s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .

HY-10206

Amuvatinib 5+ Cited Publications MP470; HPK 56	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET Apoptosis	Cancer
Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, *PDGFRα, Flt3, c-Met* and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-13049

Cediranib maleate 10+ Cited Publications AZD-2171 maleate	VEGFR Autophagy PDGFR	Cancer
Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-100315

XL 999 Tyrosine kinase-IN-1	VEGFR PDGFR FGFR	Cardiovascular Disease Cancer
XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC₅₀ values for KDR, Flt-1, FGFR1 and *PDGFRα* of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer .

HY-111507

PDGFRα kinase inhibitor 1 1 Publications Verification	PDGFR	Cancer
PDGFRα kinase inhibitor 1 is a highly selective type II *PDGFRα* kinase inhibitor with IC₅₀s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively .

HY-P99223

Tovetumab MEDI-575	PDGFR	Cancer
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .

HY-W011266

JNJ-10198409 1 Publications Verification	PDGFR	Cancer
JNJ-10198409 is a relatively selective, orally active, and ATP competitive *PDGF-RTK* (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC₅₀=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against *PDGFR-β* kinase (IC₅₀=4.2 nM) and *PDGFR-α* kinase (IC₅₀=45 nM) .

HY-W143698

PDGFRα kinase inhibitor 2	Bcr-Abl c-Kit PDGFR	Cancer
PDGFRα kinase inhibitor 2 (compound 1), an Imatinib (HY-15463) analogue, is a covalent and irreversible kinase inhibitor with IC₅₀s of 6.95 μM, 2.45 μM, 1.39 μM for ABL1 wt, KIT wt, PDGFRR wt .

HY-12047S

Ponatinib-d8 AP24534-d₈	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib-d₈ (AP24534-d₈) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-15814

HG-7-85-01	Bcr-Abl PDGFR c-Kit Src JAK Apoptosis	Cancer
HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, *PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR* and RET with IC₅₀s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC₅₀>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression .

HY-100368

MELK-8a 3 Publications Verification NVS-MELK8a	PDGFR Haspin Kinase MELK Mitosis	Cancer
MELK-8a (NVS-MELK8a) is a highly potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor with IC₅₀ of 2 nM. MELK-8a also inhibits Flt3 (ITD), Haspin, PDGFRα with IC₅₀s of 0.18, 0.19, and 0.42 μM, respectively. MELK plays an essential role in regulating cell mitosis in a subset of cancer cells .

HY-13493

AC710	PDGFR c-Kit FLT3	Cancer
AC710 is a potent *PDGFR* inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

HY-10987

ENMD-2076 Tartrate 4 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR Src PDGFR Apoptosis	Cancer
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, *PDGFRα*, respectively.

HY-101489A

GZD856 formic	PDGFR Bcr-Abl Apoptosis	Cancer
GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC₅₀s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-Abl ^T315I inhibitor, with IC₅₀s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity . GZD856 (formic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-171878

BI-4659	TGF-β Receptor PDGFR TGF-beta/Smad	Inflammation/Immunology Cancer
BI-4659 is a TGFβRI and *PDGFRα* inhibitor with IC₅₀ values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and *PDGFRα, blocks the downstream TGFβRI* signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury .

HY-108766R

Ponatinib hydrochloride (Standard) AP24534 hydrochloride (Standard)	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy Reference Standards	Infection Cancer
Ponatinib (hydrochloride) (Standard) is the analytical standard of Ponatinib (hydrochloride). This product is intended for research and analytical applications. Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, **PDGFRβ/PDGFRα, and ERK1/ERK2**, respectively .

HY-162888

WQ-C-401	PDGFR ERK	Cardiovascular Disease
WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking *PDGFR* autophosphorylation in a concentration-dependent manner, with EC₅₀ values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .

HY-10206A

Amuvatinib hydrochloride MP470 hydrochloride; HPK 56 hydrochloride	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET	Cancer
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, *PDGFRα, Flt3, c-Met* and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-175540

PDGFRα kinase-IN-2	PDGFR	Cardiovascular Disease Cancer
PDGFRα kinase-IN-2 is a potent *PDGFR-α* inhibitor with an IC₅₀ of 2.1 nM. PDGFRα kinase-IN-2 exhibits anticancer activity against human colon cancer HT-29 cell with an IC₅₀ of 1.48 μM. PDGFRα kinase-IN-2 has anti-angiogenic activity in zebrafish models and low embryonic lethality. PDGFRα kinase-IN-2 can used for the studies of colon cancer and anti-angiogenesis .

HY-173275

PDGFRα kinase inhibitor 3	PDGFR	Cancer
PDGFRα kinase inhibitor 3 (Compound L7) is a highly potent inhibitor targeting the PDGFRα ^D842V kinase with IC₅₀s values of 23.8 nM and 2.1 nM in biochemical and cellular assays, respectively. PDGFRα kinase inhibitor 3 binds to the ATP-binding pocket of PDGFRα ^D842V to block its downstream signaling pathways and inhibit kinase activity. PDGFRα kinase inhibitor 3 can be used for gastrointestinal stromal tumors (GISTs) study .

HY-B0062

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively .

HY-163471

PDGFRα/β/VEGFR-2-IN-1	PDGFR VEGFR	Cancer
PDGFRα/β/VEGFR-2-IN-1 (6f), a multiple PDGFRα/ and VEGFR-2 tyrosine kinase inhibitor, particularly targets PDGFRα, PDGFRβ, and VEGFR-2 kinases with Nano molar concentrations .

HY-145904

PDGFRα/FLT3-ITD-IN-3	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of 0.153 and 0.004 μM, respectively. PDGFRα/FLT3-ITD-IN-3 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-145902

PDGFRα/FLT3-ITD-IN-1	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-145903

PDGFRα/FLT3-ITD-IN-2	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-2 (Compound 13d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 20 and 1.654 μM, respectively. PDGFRα/FLT3-ITD-IN-2 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .

HY-12047R

Ponatinib (Standard) AP24534 (Standard)	Reference Standards Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (Standard) is the analytical standard of Ponatinib. This product is intended for research and analytical applications. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, *PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-13493A

AC710 Mesylate	PDGFR	Cancer
AC710 Mesylate is a potent *PDGFR* inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

HY-144653

PDGFR-IN-1	PDGFR Apoptosis	Cancer
PDGFR-IN-1 (compound 7m) is a potent and orally active *PDGFR* (platelet-derived growth factor receptor) inhibitor, with IC₅₀ values of 2.4 and 0.9 nM for *PDGFRα* and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma .

HY-13049R

Cediranib maleate (Standard) AZD-2171 maleate (Standard)	VEGFR Autophagy PDGFR Reference Standards	Cancer
Cediranib (maleate) (Standard) is the analytical standard of Cediranib (maleate). This product is intended for research and analytical applications. Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-10205R

Cediranib (Standard) AZD2171 (Standard)	Reference Standards VEGFR Autophagy PDGFR	Cancer
Cediranib (Standard) is the analytical standard of Cediranib. This product is intended for research and analytical applications. Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

HY-168115

Multi-kinase inhibitor 4	FLT3 PDGFR	Cancer
Multi-kinase inhibitor 4 (compound 14) is an orally active inhibitor of FLT1, KDR, FLT3, FLT4, *PDGFRα, PDGFRβ, with IC₅₀*s of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, 0.89 nM. Multi-kinase inhibitor 4 plays an important role in cancer research .

HY-164387

Sutetinib	EGFR PDGFR VEGFR	Cancer
Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (K_i= 0.009 µM for VEGFR-1/2/3), *PDGFR* (K_i= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo .

HY-160689

GW694590A UNC10112731	c-Myc c-Kit Discoidin Domain Receptor PDGFR	Others
GW694590A (UNC10112731) is a MYC protein stabilizer that increases endogenous MYC protein levels. GW694590A also targets receptor tyrosine kinases, inhibiting DDR2, KIT and *PDGFRα* by 81% at 1 μM. , 68% and 67%. GW694590A is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential effects on the Fluc reporter gene .

HY-101489

GZD856	PDGFR Bcr-Abl Apoptosis	Cancer
GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC₅₀s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-Abl ^T315I inhibitor, with IC₅₀s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity .

HY-164387A

Sutetinib maleate	EGFR VEGFR PDGFR	Cancer
Sutetinib maleate is the maleate form of Sutetinib (HY-164387). Sutetinib maleate is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (K_i= 0.009 µM for VEGFR-1/2/3), *PDGFR* (K_i= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib maleate inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo .

HY-10206R

Amuvatinib (Standard) MP470 (Standard); HPK 56 (Standard)	Reference Standards c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET Apoptosis	Cancer
Amuvatinib (Standard) is the analytical standard of Amuvatinib. This product is intended for research and analytical applications. Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-168114

Multi-kinase inhibitor 3	FLT3 PDGFR VEGFR	Cancer
Multi-kinase inhibitor 3 (compound 12) is a potent and orally active multikinase inhibitor with IC₅₀ values of 1.59, 1.23, 1.19, 0.59, 0.22, 1.15 nM for FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, PDGFRβ, respectively. Multi-kinase inhibitor 3 shows antiproliferative activity. Multi-kinase inhibitor 3 shows anticancer activity .

HY-123586

L-783277	MEK VEGFR FLT3 PDGFR	Cancer
L-783277 (Compound 4) is a MEK inhibitor (IC₅₀ = 4 nM). L-783277 has potent inhibitory activity against a variety of kinases, including VEGFR2/3, FLT1/3/4, MEK1/2, KDR, and *PDGFRα, but has low selectivity for the kinase community. L-783277 inhibits viability (IC₅₀* = 22 mM) and cell proliferation (IC₅₀ = 21 mM) of H295R cells. L-783277 could be used in research on cancers such as adrenocortical carcinoma .

HY-176194

Antifibrotic agent 1	Collagen c-Fms PDGFR Src	Inflammation/Immunology
Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, *PDGFR-α* and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model .

HY-161843

Necroptosis-IN-4	Necroptosis RIP kinase	Inflammation/Immunology
Necroptosis-IN-4, a potent necroptosis inhibitor, is a RIP kinase 1 (RIPK1) inhibitor. Necroptosis-IN-4 has no inhibitory activity against RIPK3 and weak inhibitory activity against VEGFR1/2 and PDGFR-α .

HY-112352

SU9518	Endogenous Metabolite	Others
SU9518 is a tyrosine kinase inhibitor with specific activity against PDGFRα. SU9518 can inhibit the development of proliferative vitreoretinopathy (PVR) in fibroblast and Muller cell rabbit models. SU9518 showed effective inhibitory effects in these models without toxic effects. Therefore, SU9518 has the potential to be used to inhibit PVR in humans and other proliferative eye diseases involving fibrosis and gliosis .

HY-P991758

*Anti-Mouse PDGFRα* Antibody (APA5)**	PDGFR	Cardiovascular Disease
Anti-Mouse PDGFRα Antibody (APA5) reacts with mouse *PDGFRα. Anti-Mouse PDGFRα* Antibody (APA5) can be used to block PDGFRα in vitro and in vivo. Anti-Mouse PDGFRα Antibody (APA5) can be used for the study of pulmonary hypertension. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .

Cat. No.	Product Name	Target	Research Area	Image